Evidence map›Paper›PMID 32577649›Full record

ArticlebioRxiv : the preprint server for biology2020

Morphological Cell Profiling of SARS-CoV-2 Infection Identifies Drug Repurposing Candidates for COVID-19.

Carmen Mirabelli, Jesse W Wotring, Charles J Zhang, Sean M McCarty, Reid Fursmidt, Tristan Frum, Namrata S Kadambi, Anya T Amin, Teresa R O'Meara, Carla D Pretto and 10 more

Registry-linked trialOpen access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04526821 (Bovine Lactoferrin for the Prevention of COVID-19 Infection in Physicians and Nurses in Hospitals in Lima, Peru), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04526821 phase2terminatednot on this map

Bovine Lactoferrin for the Prevention of COVID-19 Infection in Physicians and Nurses in Hospitals in Lima, Peru: a Double Blinded Randomized Clinical Trial (LF-COVID)

TypeinterventionalSponsorUniversidad Peruana Cayetano HerediaRan2020 to 2021Enrolled209ConditionsSARS-CoV-2ArmsBovine Lactoferrin, Maltodextrin
3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 101 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 3 institutions in 2 countries.

Carmen MirabelliDepartment of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, MI, 48109, USA.
Jesse W WotringDepartment of Medicinal Chemistry, College of Pharmacy, University of Michigan, Ann Arbor, MI, 48109, USA.
Charles J ZhangDepartment of Medicinal Chemistry, College of Pharmacy, University of Michigan, Ann Arbor, MI, 48109, USA.
Sean M McCartyDepartment of Medicinal Chemistry, College of Pharmacy, University of Michigan, Ann Arbor, MI, 48109, USA.
Reid FursmidtDepartment of Internal Medicine, Gastroenterology, Michigan Medicine at the University of Michigan, Ann Arbor, MI, 48109, USA.
Tristan FrumDepartment of Cell and Developmental Biology, University of Michigan, Ann Arbor, MI, 48109, USA.
Namrata S KadambiDepartment of Internal Medicine, Gastroenterology, Michigan Medicine at the University of Michigan, Ann Arbor, MI, 48109, USA.
Anya T AminDepartment of Internal Medicine, Gastroenterology, Michigan Medicine at the University of Michigan, Ann Arbor, MI, 48109, USA.
Teresa R O'MearaDepartment of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, MI, 48109, USA.
Carla D PrettoDepartment of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, MI, 48109, USA.
Jason R SpenceDepartment of Internal Medicine, Gastroenterology, Michigan Medicine at the University of Michigan, Ann Arbor, MI, 48109, USA.
Jessie HuangCenter for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA, 02118, USA.
Konstantinos D AlysandratosCenter for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA, 02118, USA.
Darrell N KottonCenter for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA, 02118, USA.
Samuel K HandelmanDepartment of Internal Medicine, Gastroenterology, Michigan Medicine at the University of Michigan, Ann Arbor, MI, 48109, USA.
Christiane E WobusDepartment of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, MI, 48109, USA.
Kevin J WeatherwaxU-M Center for Drug Repurposing, University of Michigan, Ann Arbor, MI, 48109, USA.
George A MashourU-M Center for Drug Repurposing, University of Michigan, Ann Arbor, MI, 48109, USA.
Matthew J O'MearaDepartment of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, 48109, USA.
Jonathan Z SextonDepartment of Medicinal Chemistry, College of Pharmacy, University of Michigan, Ann Arbor, MI, 48109, USA.
University of Michigan · USBoston University · USMichigan Medicine · US

Funding

Michigan Institute for Clinical and Health Research (MICHR)UL1TR002240 · NCATS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LUMENG, JULIE C, MASHOUR, GEORGE ALEXANDER · 2017 to 2022
$54.9M
University of Michigan Center for Gastrointestinal ResearchP30DK034933 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI OWYANG, CHUNG · 1986 to 2021
$22.5M
Pilot and Feasibility (P and F) ProgramP30DK089503 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Kanakadurga Singer · 2010 to 2026
$20.3M
Tissue Engineering and RegenerationT32DE007057 · NIDCR · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI DAVID H. KOHN · 1985 to 2026
$17.3M
Stem Cell Differentiation CoreU19AI116482 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SPENCE, JASON, TAKAYAMA, SHUICHI · 2015 to 2019
$6.4M
Supplement to a Hox-Wnt-Sox signaling axis regulates lung development, patterning and branchingR01HL119215 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SPENCE, JASON · 2013 to 2021
$4.2M
Small molecules for expansion of islet beta-cell mass in diabetesR01DK120623 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI NEWGARD, CHRISTOPHER B, SEXTON, JONATHAN ZACHARY · 2019 to 2021
$2.0M
Michigan Institute for Clinical and Health Research (MCHR)KL2TR000434 · NCATS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MASHOUR, GEORGE ALEXANDER · 2012 to 2016
$1.7M
NCATS NIH HHS KL2 TR000434NCATS NIH HHS UL1 TR002240NHLBI NIH HHS R01 HL119215NIAID NIH HHS U19 AI116482NIDCR NIH HHS T32 DE007057NIDDK NIH HHS P30 DK034933NIDDK NIH HHS P30 DK089503NIDDK NIH HHS R01 DK120623
6 · The paper itself

Abstract

The global spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and the associated disease COVID-19, requires therapeutic interventions that can be rapidly identified and translated to clinical care. Traditional drug discovery methods have a >90% failure rate and can take 10-15 years from target identification to clinical use. In contrast, drug repurposing can significantly accelerate translation. We developed a quantitative high-throughput screen to identify efficacious agents against SARS-CoV-2. From a library of 1,425 FDA-approved compounds and clinical candidates, we identified 17 dose-responsive compounds with

Identifiers

PMID32577649
PMCPMC7302203
OpenAlexW3029941820

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.